Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC
NCT04629027
·
clinicaltrials.gov ↗
UNKNOWN
Status
80
Enrollment
OTHER
Sponsor class
Conditions
Non Small Cell Lung Cancer
Interventions
DRUG:
Immune checkpoint inhibitor
Sponsor
Peking University Cancer Hospital & Institute